Safety notice

MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy

Safety notice from a federal regulator

Headline as published by U.S. Food and Drug Administration (MedWatch) on Nov 6, 2026; collected by the wire Nov 9, 2026, 11:00 AM ET.

Read at U.S. Food and Drug Administration (MedWatch)

FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy: FDA Safety Communication

From U.S. Food and Drug Administration (MedWatch)’s feed

Coverage

  1. U.S. Food and Drug Administration (MedWatch) Federal regulators

    MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy

Named in this story

Topics

Explore the named firms, organizations and MDL dockets above. Sources and method